Screening and optimization of fusion inhibitors of Respiratory Syncytial Virus

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

12868.1;9 PFLS-LS

Projekttitel

Screening and optimization of fusion inhibitors of Respiratory Syncytial Virus

Projekttitel Englisch

Screening and optimization of fusion inhibitors of Respiratory Syncytial Virus

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Screening and optimization of fusion inhibitors of Respiratory Syncytial Virus
Abstract (Englisch)	Respiratory syncytial virus infections are one of the leading causes of mortality in infants worldwide and cause a significant hospitalization burden both in the US and in Europe. There is currently only one treatment available, a prophylactic antibody (Synagis/Palivizumab) that is administered only to at risk premature infants because of its highly prohibitive cost. This project aims at screening pre-fractionated melusine venoms and rationally drug designed stapled peptides to identify molecules that inhibit virus entry into host cells.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Screening and optimization of fusion inhibitors of Respiratory Syncytial Virus

Abstract
(Englisch)

Respiratory syncytial virus infections are one of the leading causes of mortality in infants worldwide and cause a significant hospitalization burden both in the US and in Europe. There is currently only one treatment available, a prophylactic antibody (Synagis/Palivizumab) that is administered only to at risk premature infants because of its highly prohibitive cost. This project aims at screening pre-fractionated melusine venoms and rationally drug designed stapled peptides to identify molecules that inhibit virus entry into host cells.